Abbott Laboratories stock research
FY2026 Q1
Abbott Laboratories (ABT) Gross Margin & Quarterly History
Explore Abbott Laboratories (ABT) gross margin from 2023 through the latest reported quarter, using SEC-sourced revenue, gross profit, and direct costs.
Gross margin takeaway
Quarter ended Mar 31, 2026 · FY2026 Q1
For the quarter, revenue and gross profit both decreased sequentially, while cost of revenue remained flat, resulting in a lower gross margin. Compared to the same quarter last year, revenue and gross profit increased, but cost of revenue rose at a faster pace, leading to a slightly weakened gross margin.
- The most observable driver of the gross margin change was the relationship between revenue and cost of revenue. Sequentially, cost of revenue held steady despite a decline in revenue, compressing the margin.
- Gross margin decreased from the prior quarter and from the same quarter a year ago. The decline was more pronounced sequentially due to stable costs with lower revenue.
Gross margin snapshot
The selected quarter's reported revenue, gross profit, direct costs, and margin comparisons.
Gross margin
56.2%
Gross profit
$6.3B
Revenue
$11.2B
Cost of revenue
$4.9B
Quarter-over-quarter change
-0.8 pts
Year-over-year change
-0.7 pts
Quarterly gross margin trend
A four-quarter view of the revenue and direct-cost bridge behind gross margin.
| Period | Revenue | Gross profit | Cost of revenue | Gross margin |
|---|---|---|---|---|
| Jun 30, 2025 | $11.1B | $6.3B | $4.9B | 56.4% |
| Sep 30, 2025 | $11.4B | $6.3B | $5.1B | 55.4% |
| Dec 31, 2025 | $11.5B | $6.5B | $4.9B | 57.0% |
| Mar 31, 2026 | $11.2B | $6.3B | $4.9B | 56.2% |
Quarterly comparisons
Compare the selected margin with the preceding quarter and the same fiscal quarter one year earlier.
Previous-quarter change
Dec 31, 2025
-0.8 pts
Year-over-year change
Mar 31, 2025
-0.7 pts
What the margin says
Filing-constrained interpretation of margin direction, comparisons, and what to monitor next.
The most observable driver of the gross margin change was the relationship between revenue and cost of revenue. Sequentially, cost of revenue held steady despite a decline in revenue, compressing the margin.
Gross margin decreased from the prior quarter and from the same quarter a year ago. The decline was more pronounced sequentially due to stable costs with lower revenue.
Monitor the integration of the Exact Sciences acquisition as noted in the filing, particularly its effect on cost structure and gross margin.
Peer context
Latest available gross margins for related public companies.
| Company | Gross margin |
|---|---|
| Abbott Laboratories (ABT) | 56.2% |